研究業績

研究・業績

業績

  • 2026年
    1. Shiga T, Nozaki Y, Tsuchimoto S, Yamazawa H, Ashida C, Tomita D, Itami T, Hino S, Sugiyama M, Morita Y, Kinoshita K, Rai S. Diagnostic performance of HScore for macrophage activation syndrome complicating Still's disease in adults: a multicentre case-control study. Rheumatology (Oxford). 2026 Aug 31:keag473. doi: 10.1093/rheumatology/keag473. Epub ahead of print. PMID: 42671130.
    2. Etani Y, Okita Y, Maeda Y, Tsujimoto K, Noguchi T, Watanabe R, Hashimoto M, Shirasugi I, Nakano N, Nozaki Y, Ashida C, Son Y, Makino H, Wada Y, Yoshikawa A, Fujii T, Yamamoto W, Kumanogoh A, Okada S, Nakata K, Ebina K. Real-world comparison of herpes zoster risk among five Janus kinase inhibitors in rheumatoid arthritis: The ANSWER cohort study. Joint Bone Spine. 2026 May 26;93(5):106080. doi: 10.1016/j.jbspin.2026.106080. Epub ahead of print. PMID: 42202903.
    3. Fujiki H, Watanabe R, Ishihara R, Katsushima M, Fujisawa Y, Onishi A, Tsuji H, Kotani T, Wada Y, Nozaki Y, Shiga T, Sumitomo S, Oka H, Miyake H, Fujii T, Iwata S, Kato Y, Itotagawa E, Yamamoto W, Fujita Y, Fukumoto K, Yamada S, Hashimoto M. Factors Associated with Glucocorticoid Withdrawal in Systemic Lupus Erythematosus: A Multicentre ANSWER-SLE Cohort. Mod Rheumatol. 2026 Aug 13:roag065. doi: 10.1093/mr/roag065. Epub ahead of print. PMID: 42593757.
    4. Miyake H, Onishi A, Tsuji H, Kotani T, Wada Y, Nozaki Y, Shiga T, Iwata S, Fujii T, Kato Y, Itotagawa E, Sumitomo S, Oka H, Yamamoto W, Katsushima M, Hashimoto M. Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study. Mod Rheumatol. 2026 Jun 26:roag053. doi: 10.1093/mr/roag053. Epub ahead of print. PMID: 42360362.
    5. Murata K, Fujii T, Ebina K, Etani Y, Katayama M, Nozaki Y, Ashida C, Okano T, Hashimoto M, Kotani T, Shiba H, Son Y, Yoshida N, Shirasugi I, Hayashi S, Yamamoto W, Nakabo S, Murakami K, Onishi A, Tanaka M, Morinobu A, Matsuda S. Real-world clinical outcomes of patients with disproportionate articular pain in rheumatoid arthritis: ANSWER cohort study. Scand J Rheumatol. 2026 Jun 19:1-12. doi: 10.1080/03009742.2026.2680764. Epub ahead of print. PMID: 42318602.
    6. Nozaki Y, Kishimoto K, Itami T, Tomita D, Wada Y, Kotani T, Takeuchi T, Hidaka T, Hino S, Miyamoto T, Miyake H, Hatta K, Mamoto K, Yamada Y, Okano T, Okano T, Saegusa J, Horita M, Nishida K, Kinoshita K, Rai S. Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis. Rheumatology (Oxford). 2026 Jun 3;65(6):keag289. doi: 10.1093/rheumatology/keag289. PMID: 42261260; PMCID: PMC13275124.
    7. Tanaka Y, Hanami K, Miyazaki Y, Ishigatsubo Y, Iwamoto T, Ushio K, Okano Y, Onobori M, Kawahata K, Saegusa J, Nakamura Y, Natsumeda M, Nozaki Y, Miyamoto T, Yamanishi Y, Ishiguro N, Kumanogoh A, Takeuchi T, Tohma S, Fujino Y, Kameda H. Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J). RMD Open. 2026 May 12;12(2):e006446. doi: 10.1136/rmdopen-2025-006446. PMID: 42120177; PMCID: PMC13182438.
    8. Nozaki Y, Shiga T, Ri J, Itami T, Tomita D, Yamazawa H, Morimoto Y, Fukuda R, Tsuchimoto T, Morita S, Akazawa H, Murata K, Onishi A, Ebina K, Shirasugi I, Yamada H, Hashimoto M, Watanabe R, Wada Y, Takeuchi T, Amuro H, Tanaka A, Katayama M, Etani Y, Yamamoto W, Kinoshita K, Rai S. Reduced versus standard dosing of Janus kinase inhibitors in rheumatoid arthritis: a propensity score-matched real-world study accounting for poor prognostic factors. Ann Rheum Dis. 2026 Apr 27:S0003-4967(26)00213-X. doi: 10.1016/j.ard.2026.03.029. Epub ahead of print. PMID: 42049606.
    9. Etani Y, Okita Y, Tsujimoto K, Noguchi T, Murata K, Fujii T, Shirasugi I, Yamashita M, Nagai K, Yoshikawa A, Hashimoto M, Okano T, Nozaki Y, Itami T, Son Y, Makino H, Yamamoto W, Kumanogoh A, Okada S, Nakata K, Ebina K. Clinical outcomes of molecular-targeted therapies for rheumatoid arthritis: comparison between orthopaedic surgeons and rheumatologists in the multicenter retrospective ANSWER cohort. Clin Rheumatol. 2026 Jun;45(6):3101-3109. doi: 10.1007/s10067-026-08061-7. Epub 2026 Apr 1. PMID: 41920235; PMCID: PMC13249661.
    10. Nishisaka K, Okano T, Imai T, Tsubosaka M, Kamenaga T, Nakano N, Hayashi S, Yamamoto W, Onishi A, Murakami K, Tsujimoto K, Katsushima M, Yoshikawa A, Kotani T, Amuro H, Son Y, Itami T, Nozaki Y, Nose Y, Yamashita M, Shirasugi I, Yamada H, Nishimura K, Ueda Y, Sendo S, Hashimoto M, Kuroda R, Saegusa J. Mode of action-specific and cause-specific retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in anti-SS-A antibody-positive rheumatoid arthritis: The ANSWER cohort study. PLoS One. 2026 Mar 18;21(3):e0344747. doi: 10.1371/journal.pone.0344747. PMID: 41849340; PMCID: PMC12998854.
    11. Fujisawa Y, Watanabe R, Okano T, Onishi A, Murakami K, Ebina K, Yamada H, Yamashita M, Takeuchi T, Yoshikawa A, Son Y, Makino H, Nozaki Y, Itami T, Yamamoto W, Yano Y, Togashi T, Katsushima M, Fukumoto K, Yamada S, Hashimoto M. Baseline neutrophil-to-lymphocyte ratio predicts drug retention of IL-6 inhibitors and JAK inhibitors in RA: the ANSWER cohort study. Rheumatology (Oxford). 2026 Feb 4;65(2):keaf602. doi: 10.1093/rheumatology/keaf602. PMID: 41212522.
    12. Nozaki Y, Kishimoto K, Itami T, Tomita D, Wada Y, Kotani T, Takeuchi T, Hidaka T, Hino S, Miyamoto T, Miyake H, Hatta K, Mamoto K, Yamada Y, Okano T, Okano T, Saegusa J, Horita M, Nishida K, Kinoshita K, Rai S. Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis. Arthritis Res Ther. 2026 Jan 2;28(1):32. doi: 10.1186/s13075-025-03722-5. PMID: 41484643; PMCID: PMC12888330.
    13. Nozaki Y, Murata K, Onishi A, Tsujimoto K, Yamamoto W, Yamada H, Sendo S, Hashimoto M, Okano T, Shiba H, Hiramatsu Y, Son Y, Yoshida N, Fukuda R, Morimoto Y, Kishimoto K, Itami T, Tomita D, Ashida C, Shiga T, Kinoshita K. Clinical efficacy of JAK inhibitors for RA patients with poor-prognosis factors: the ANSWER cohort study. Rheumatology (Oxford). 2026 Jan 8;65(1):keaf552. doi: 10.1093/rheumatology/keaf552. PMID: 41159415.
  • 2025年
    1. Nozaki Y, Kishimoto K, Tomita D, Itami T, Ashida C, Shiga T, Yamazawa H, Ishimura K, Morimoto Y, Fukuda R, Kinoshita K. Stepwise dose reduction and discontinuation of bDMARD in rheumatoid arthritis: a prospective cohort study of flare-free population, flares, and predictive markers. Arthritis Res Ther. 2025 Nov 4;27(1):205. doi: 10.1186/s13075-025-03672-y. PMID: 41189003; PMCID: PMC12584375.
    2. Tsujimoto K, Ebina K, Okamura S, Okita Y, Etani Y, Yamamoto W, Onishi A, Onizawa H, Shirasugi I, Nakano N, Kotani T, Hiramatsu Y, Hashimoto M, Okano T, Nozaki Y, Ashida C, Son Y, Tanaka A, Hara R, Okada S, Kumanogoh A. Sustained efficacy of second-line JAK inhibitors in patients with rheumatoid arthritis: insights from the ANSWER cohort. Rheumatology (Oxford). 2025 Jul 1;64(7):4207-4217. doi: 10.1093/rheumatology/keaf157. PMID: 40111839.
    3. Ashida C, Nozaki Y, Li J, Akazawa H, Kishimoto K, Kinoshita K, Matsumura I. Urinary Kim-1 Correlates with Interstitial Nephritis Activity in Patients with Microscopic Polyangiitis. Curr Issues Mol Biol. 2025 Mar 16;47(3):196. doi: 10.3390/cimb47030196. PMID: 40136450; PMCID: PMC11941514.
    4. Onishi A, Tanaka M, Fujii T, Murata K, Murakami K, Hashimoto M, Watanabe R, Nozaki Y, Ashida C, Yamamoto W, Yamada H, Sendo S, Ebina K, Makino H, Son Y, Wada Y, Hata K, Matsuda S, Morinobu A. Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study. Arthritis Res Ther. 2025 Mar 7;27(1):52. doi: 10.1186/s13075-025-03514-x. PMID: 40055759; PMCID: PMC11887301.
  • 2024年
    1. Nozaki Y, Kishimoto K, Tomita D, Itami T, Ashida C, Kinoshita K, Matsumura I. Utility of the GerdQ questionnaire in detecting gastroesophageal symptoms with RA patients. BMC Rheumatol. 2024 Dec 23;8(1):73. doi: 10.1186/s41927-024-00442-2. PMID: 39716318; PMCID: PMC11664924.
    2. Nozaki Y, Hao Y, Barnas JL. Editorial: Treat-to-target in systemic lupus erythematosus: cytokine transduction pathways in SLE. Front Immunol. 2024 Oct 16;15:1503776. doi: 10.3389/fimmu.2024.1503776. PMID: 39478869; PMCID: PMC11521872.
    3. Nozaki Y, Akiba H, Akazawa H, Yamazawa H, Ishimura K, Kinoshita K, Matsumura I. Inhibition of the TIM-1 and -3 signaling pathway ameliorates disease in a murine model of rheumatoid arthritis. Clin Exp Immunol. 2024 Sep 16;218(1):55-64. doi: 10.1093/cei/uxae056. PMID: 38975703; PMCID: PMC11404125.
    4. Nakayama Y, Onishi A, Yamamoto W, Yoshikawa A, Shiba H, Yoshida N, Son Y, Shirasugi I, Maeda T, Katsushima M, Hashimoto M, Etani Y, Itami T, Nozaki Y, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Matsuda S, Morinobu A. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study. Clin Exp Med. 2024 May 10;24(1):97. doi: 10.1007/s10238-024-01360-w. PMID: 38727756; PMCID: PMC11087367.